Eric Shaff - Seres Therapeutics President, Chief Executive Officer, Director
| 1S9 Stock | EUR 0.85 0.03 3.41% |
CEO
Mr. Eric D. Shaff is President, Chief Executive Officer, Director of the Company. Previously, he served as our Chief Operating and Financial Officer and Executive Vice President from January 2018 until January 2019 and as our Chief Financial Officer from November 2014 until January 2019. Mr. Shaff has also served on the board of directors of Sigilon Therapeutics, Inc. From January 2012 to November 2014, Mr. Shaff was Vice President of Corporationrationrate Finance for Momenta Pharmaceuticals, a biotechnology company, where he helped manage Momentas accounting, finance, planning, and procurement functions, as well as contributing to Momentas investor relations efforts. From June 2004 to December 2011, Mr. Shaff held a number of corporate development and finance positions with Genzyme Corporationrationration, a biotechnology company, most recently as Vice President of FinanceController for the Personalized Genetic Health division since 2019.
| Age | 43 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Phone | 617 945 9626 |
| Web | https://www.serestherapeutics.com |
Eric Shaff Latest Insider Activity
Tracking and analyzing the buying and selling activities of Eric Shaff against Seres Therapeutics stock is an integral part of due diligence when investing in Seres Therapeutics. Eric Shaff insider activity provides valuable insight into whether Seres Therapeutics is net buyers or sellers over its current business cycle. Note, Seres Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Seres Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Eric Shaff over a year ago Exercise or conversion by Eric Shaff of 27838 shares of Seres Therapeutics subject to Rule 16b-3 |
Seres Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4018) % which means that it has lost $0.4018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.9017) %, meaning that it generated substantial loss on money invested by shareholders. Seres Therapeutics' management efficiency ratios could be used to measure how well Seres Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -1.9 | |||
| Return On Asset | -0.4 |
Seres Therapeutics Leadership Team
Elected by the shareholders, the Seres Therapeutics' board of directors comprises two types of representatives: Seres Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Seres. The board's role is to monitor Seres Therapeutics' management team and ensure that shareholders' interests are well served. Seres Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Seres Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeff York, VP HR | ||
| SPHR SHRMSCP, Ex Officer | ||
| Thomas DesRosier, Chief Legal Officer, Executive Vice President and Secretary | ||
| David Ege, Executive Vice President, Chief Technology Officer | ||
| Dennis Ausiello, Independent Director | ||
| Willard Dere, Independent Director | ||
| Eric Shaff, President, Chief Executive Officer, Director | ||
| David MBA, CFO VP | ||
| Carlo Tanzi, Head of Investor Relations and Corporate Communications | ||
| Kristin Ainsworth, Sr Communications | ||
| Marcus Chapman, Senior Vice President - Finance and Principal Financial and Accounting Officer | ||
| JD Esq, Exec Officer | ||
| Richard Kender, Independent Director | ||
| Lisa MD, Ex Officer | ||
| Meryl Zausner, Independent Director | ||
| Stephen Berenson, Independent Chairman of the Board | ||
| John Aunins, Executive Vice President of Bioprocess & Manufacturing and Chief Technology Officer | ||
| Matthew Henn, Executive Vice President Chief Scientific Officer | ||
| Jayne Gansler, Chief People Officer, Executive Vice President | ||
| Kurt Graves, Independent Director | ||
| Eric MBA, CEO Pres | ||
| Gregory Behar, Independent Director | ||
| Lisa Moltke, Executive Vice President Chief Medical Officer | ||
| Paul Biondi, Independent Director | ||
| Terri Young, Executive Vice President Chief Commercial and Strategy Officer |
Seres Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Seres Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.9 | |||
| Return On Asset | -0.4 | |||
| Operating Margin | (17.02) % | |||
| Current Valuation | 582.79 M | |||
| Shares Outstanding | 124.59 M | |||
| Shares Owned By Insiders | 6.66 % | |||
| Shares Owned By Institutions | 85.90 % | |||
| Price To Book | 12.02 X | |||
| Price To Sales | 50.23 X | |||
| Revenue | 144.93 M |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.